Gilead Sciences
CompanyUnited States
Gilead Sciences develops 2 assets, the furthest in phase 3 (seladelpar in primary biliary cholangitis). Mostly small molecule acting on lipid and ceramide metabolism, PPARD and inflammation; based in the United States.
- Assets
- 2
- Furthest
- Phase 3
- Trials
- 28
- Signals
- 1
Pipeline
2Selective PPAR-delta receptor agonist that regulates bile acid synthesis, inflammation, and lipid metabolism.
Phase 3Small moleculeLipid and ceramide metabolismPPARDprimary biliary cholangitis
GLP-1 receptor agonist
Phase 1Small moleculeInsulin/IGF-1 signallingGLP1R
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms5
- Trials34
- Signals1
- Similar companies6
Papers
Updated 7 Oct 2026 · 38 sources